Vistagen Therapeutics, Inc. VTGN
Set alert
At close · Oct 30
After hours · Oct 30, 7:56 PM ET
- YTD
- -74.50%
- 1 year
- -95.51%
- Open
- 0.1707
- Prev close
- 0.1707
- Mkt cap
- 7.47M
- Vol
- 594.79K
- Avg vol
- 12.32M
- EPS
- -1.66
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.1655
- High
- 0.172
- Forward P/E
- -1.49
- Beta
- 0.00
- Short ratio
- 1.69
- Inst. own
- 53.63%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Feb 11, 2025
- 50-d avg
- 2.81
- 200-d avg
- 3.60
- 1y target
- 13.00
5D chart
Signals (108)
| Name | Time | Ago |
|---|---|---|
| SMA: Bearish | Oct 30, 4:00 PM | 2 days ago |
| SMA: Bearish | Oct 30, 4:00 PM | 2 days ago |
| MACD: Sell Signal | Oct 30, 4:00 PM | 2 days ago |
| SMA: Bullish | Oct 30, 3:50 PM | 2 days ago |
| SMA: Bullish | Oct 30, 3:45 PM | 2 days ago |
| SMA: Bearish | Oct 30, 3:40 PM | 2 days ago |
| SMA: Bearish | Oct 30, 3:35 PM | 2 days ago |
| SMA: Bullish | Oct 30, 3:25 PM | 2 days ago |
| MACD: Buy Signal | Oct 30, 3:25 PM | 2 days ago |
| SMA: Bullish | Oct 30, 3:20 PM | 2 days ago |
| SMA: Bearish | Oct 30, 3:05 PM | 2 days ago |
| SMA: Bullish | Oct 30, 2:55 PM | 2 days ago |
| SMA: Bearish | Oct 30, 2:45 PM | 2 days ago |
| SMA: Bullish | Oct 30, 2:40 PM | 2 days ago |
| SMA: Bearish | Oct 30, 2:25 PM | 2 days ago |
| SMA: Bullish | Oct 30, 1:45 PM | 2 days ago |
| SMA: Bearish | Oct 30, 1:40 PM | 2 days ago |
| MACD: Sell Signal | Oct 30, 1:40 PM | 2 days ago |
| SMA: Bearish | Oct 30, 1:35 PM | 2 days ago |
| SMA: Bullish | Oct 30, 1:05 PM | 2 days ago |
| SMA: Bearish | Oct 30, 1:00 PM | 2 days ago |
| SMA: Bullish | Oct 30, 12:10 PM | 2 days ago |
| SMA: Bullish | Oct 30, 12:10 PM | 2 days ago |
| SMA: Bullish | Oct 30, 11:35 AM | 2 days ago |
| SMA: Bearish | Oct 30, 11:30 AM | 2 days ago |
| SMA: Bullish | Oct 30, 11:20 AM | 2 days ago |
| MACD: Buy Signal | Oct 30, 11:00 AM | 2 days ago |
| SMA: Bullish | Oct 30, 10:45 AM | 2 days ago |
| RSI: Oversold | Oct 30, 9:50 AM | 2 days ago |
| SMA: Bearish | Oct 29, 3:35 PM | 3 days ago |
| SMA: Bearish | Oct 29, 3:35 PM | 3 days ago |
| MACD: Sell Signal | Oct 29, 3:35 PM | 3 days ago |
| SMA: Bullish | Oct 29, 3:30 PM | 3 days ago |
| SMA: Bullish | Oct 29, 3:30 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 3:30 PM | 3 days ago |
| SMA: Bearish | Oct 29, 3:20 PM | 3 days ago |
| MACD: Sell Signal | Oct 29, 1:45 PM | 3 days ago |
| SMA: Bearish | Oct 29, 1:25 PM | 3 days ago |
| SMA: Bullish | Oct 29, 1:20 PM | 3 days ago |
| SMA: Bearish | Oct 29, 12:50 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 11:50 AM | 3 days ago |
| SMA: Bullish | Oct 29, 11:30 AM | 3 days ago |
| SMA: Bullish | Oct 29, 11:25 AM | 3 days ago |
| SMA: Bearish | Oct 29, 11:00 AM | 3 days ago |
| SMA: Bullish | Oct 29, 10:55 AM | 3 days ago |
| SMA: Bearish | Oct 29, 10:45 AM | 3 days ago |
| MACD: Sell Signal | Oct 29, 10:45 AM | 3 days ago |
| SMA: Bearish | Oct 29, 10:40 AM | 3 days ago |
| SMA: Bullish | Oct 29, 9:55 AM | 3 days ago |
| SMA: Bearish | Oct 29, 9:45 AM | 3 days ago |
| SMA: Bullish | Oct 29, 9:30 AM | 3 days ago |
| SMA: Bullish | Oct 29, 9:30 AM | 3 days ago |
| MACD: Buy Signal | Oct 29, 9:30 AM | 3 days ago |
| MACD: Sell Signal | Oct 28, 3:55 PM | 4 days ago |
| RSI: Oversold | Oct 28, 3:55 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 3:30 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 3:25 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 3:20 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:55 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 2:20 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:05 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:05 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 11:35 AM | 4 days ago |
| RSI: Oversold | Oct 28, 11:00 AM | 4 days ago |
| SMA: Bearish | Oct 28, 10:45 AM | 4 days ago |
| MACD: Sell Signal | Oct 28, 10:45 AM | 4 days ago |
| MACD: Buy Signal | Oct 28, 10:40 AM | 4 days ago |
| SMA: Bullish | Oct 28, 10:30 AM | 4 days ago |
| RSI: Oversold | Oct 28, 10:10 AM | 4 days ago |
| RSI: Oversold | Oct 28, 9:50 AM | 4 days ago |
| MACD: Sell Signal | Oct 28, 9:35 AM | 4 days ago |
| MACD: Buy Signal | Oct 27, 3:35 PM | 5 days ago |
| RSI: Oversold | Oct 27, 3:10 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 1:05 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 12:55 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 12:15 PM | 5 days ago |
| SMA: Bearish | Oct 27, 11:45 AM | 5 days ago |
| MACD: Buy Signal | Oct 27, 11:20 AM | 5 days ago |
| SMA: Bullish | Oct 27, 11:15 AM | 5 days ago |
| MACD: Sell Signal | Oct 27, 11:05 AM | 5 days ago |
| SMA: Bullish | Oct 27, 10:20 AM | 5 days ago |
| SMA: Bullish | Oct 27, 10:20 AM | 5 days ago |
| MACD: Buy Signal | Oct 27, 10:20 AM | 5 days ago |
| SMA: Bearish | Oct 27, 10:15 AM | 5 days ago |
| SMA: Bearish | Oct 27, 10:15 AM | 5 days ago |
| MACD: Sell Signal | Oct 27, 10:15 AM | 5 days ago |
| SMA: Bullish | Oct 27, 10:10 AM | 5 days ago |
| SMA: Bullish | Oct 27, 10:10 AM | 5 days ago |
| MACD: Buy Signal | Oct 27, 10:10 AM | 5 days ago |
| SMA: Bearish | Oct 27, 9:45 AM | 5 days ago |
| SMA: Bearish | Oct 27, 9:45 AM | 5 days ago |
| MACD: Sell Signal | Oct 27, 9:45 AM | 5 days ago |
| SMA: Bullish | Oct 26, 3:55 PM | 6 days ago |
| SMA: Bearish | Oct 26, 3:40 PM | 6 days ago |
| SMA: Bullish | Oct 26, 3:35 PM | 6 days ago |
| SMA: Bearish | Oct 26, 3:25 PM | 6 days ago |
| SMA: Bullish | Oct 26, 2:55 PM | 6 days ago |
| SMA: Bullish | Oct 26, 2:50 PM | 6 days ago |
| SMA: Bearish | Oct 26, 2:40 PM | 6 days ago |
| SMA: Bearish | Oct 26, 2:40 PM | 6 days ago |
| SMA: Bullish | Oct 26, 2:20 PM | 6 days ago |
| SMA: Bullish | Oct 26, 2:00 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 2:00 PM | 6 days ago |
| SMA: Bearish | Oct 26, 12:25 PM | 6 days ago |
| SMA: Bullish | Oct 26, 12:15 PM | 6 days ago |
| SMA: Bearish | Oct 26, 11:30 AM | 6 days ago |
| SMA: Bullish | Oct 26, 10:40 AM | 6 days ago |
| SMA: Bearish | Oct 26, 10:30 AM | 6 days ago |
News
-
1 day ago benzinga.com
Vistagen Therapeutics Implements 31% Workforce Reduction On October 26, 2026; Workforce Reduction Expected To Save $3.20M In Salary And Benefits Annually
On October 26, 2026, Vistagen Therapeutics, Inc. (the "Company") implemented a Board-approved reduction in workforce by approximately 31%, retaining core clinical, regulatory, technical, and corporate
1 week ago globenewswire.com
Vistagen Selects GATC Health to Apply Predictive AI Across Lead Clinical-Stage Drug Development Programs
Collaboration combines Vistagen's neuroscience expertise and datasets with GATC Health's predictive modeling capabilities to provide additional insights for protocol development and resource…
1 month ago schaeffersresearch.com
2 Falling Stocks Call Traders Are Targeting Today
Options traders are buying the dip in two stocks this morning, with Meta Platforms (NASDAQ:META) and Vistagen Therapeutics (NASDAQ:VTGN) drawing bullish options activity as both equities trade lower.
1 month ago benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Apimeds Pharmaceuticals (AMEX:APUS) shares increased by 162.4% to $6.01 during Thursday's regular session. The market value of their outstanding shares is at $3.4 million. Surrozen…
-
1 month ago benzinga.com
Vistagen Presents Exploratory Data At Psych Congress 2026 Highlighting Potential Efficacy Signal For Phase 3 Fasedienol Nasal Spray In Patients With Very Severe Social Anxiety Disorder
Exploratory research results presented at Psych Congress 2026 in New OrleansFull poster presentation can be found on "Publications" section of Company’s websiteSOUTH SAN FRANCISCO, Calif., Sept. 24,…
1 month ago globenewswire.com
Vistagen Reports Positive Findings Supporting Fasedienol's Potential in Very Severe Social Anxiety Disorder
Exploratory research results presented at Psych Congress 2026 in New Orleans Full poster presentation can be found on “Publications” section of Company's website SOUTH SAN FRANCISCO, Calif., Sept.…
1 month ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Artelo Biosciences (NASDAQ:ARTL) shares rose 216.1% to $13.12 during Wednesday's regular session. The market value of their outstanding shares is at $2.2 million. Vistagen Therapeutics…
1 month ago benzinga.com
Penny Stock Vistagen Analyst Highlights Caution after Anxiety Data
Vistagen Inc. (NASDAQ:VTGN) surged on Wednesday after preliminary findings from the open-label extension portion of its PALISADE-4 Phase 3 trial evaluating intranasal fasedienol for acute social…
1 month ago benzinga.com
Penny Stock Vistagen Analyst Highlights Caution after Anxiety Data
Vistagen reports positive preliminary Phase 3 data showing fasedienol nasal spray reduces social anxiety with strong safety results.
-
1 month ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers IM Cannabis (NASDAQ:IMCC) stock rose 56.3% to $6.47 during Wednesday's pre-market session. The company's market cap stands at $2.5 million. Vistagen Therapeutics (NASDAQ:VTGN) shares…
1 month ago benzinga.com
Why Worthington Enterprises Shares Are Trading Higher By Around 16%; Here Are 20 Stocks Moving Premarket
Worthington Enterprises surged 15.9% premarket after beating Q1 EPS and sales estimates; Wheeler REIT led gainers, while Jaguar Health and Biomea fell.
1 month ago globenewswire.com
Vistagen Announces Preliminary Positive Data from Open-Label Extension Portion of PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder
Fasedienol nasal spray was well-tolerated in patients with social anxiety disorder with no new drug-related safety findings after as-needed use for up to 12 months
1 month ago globenewswire.com
Vistagen to Present at Psych Congress 2026
Poster presentation highlights positive efficacy signal for fasedienol nasal spray in study participants with very severe social anxiety disorder Poster presentation highlights positive efficacy…
-
2 months ago benzinga.com
VistaGen Therapeutics Q1 EPS $(0.30) Beats $(0.36) Estimate, Sales $1.476M Beat $250.000K Estimate
VistaGen Therapeutics (NASDAQ:VTGN) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.36) by 16.67 percent. This is a 36.17 percent increase over losses…
2 months ago globenewswire.com
Vistagen Reports Fiscal Year 2027 First Quarter Financial Results and Corporate Update
Exploratory analyses of patients with very severe social anxiety disorder demonstrated nominally statistically significant improvement in recently reported clinical studies
2 months ago globenewswire.com
Vistagen Announces Topline Results for Repeat Dose Study of Fasedienol for Acute Treatment of Social Anxiety Disorder
Repeat dose of fasedienol demonstrated favorable safety and tolerability similar to single dose Efficacy signals were observed across primary and secondary endpoints in repeat dose and single dose…
-
2 months ago benzinga.com
SRX Global Acquires Stake In Vistagen Therapeutics; Deal Terms Were Undisclosed
The Company views Vistagen shares as undervalued and welcomes constructive engagement with its leadership team and Board of Directors to discuss ideas on how to unlock shareholder value.
2 months ago globenewswire.com
SRX Global Acquires Stake in Vistagen Therapeutics (NASDAQ: VTGN)
NORTH PALM BEACH, Fla., Aug. 04, 2026 (GLOBE NEWSWIRE) -- SRX Global Inc. (NYSE American: SRXH) (the “Company”, or “SRX”), an AI-enabled platform dedicated to generating long-term shareholder value…
3 months ago globenewswire.com
Vistagen Appoints Douglas J. Williamson to its Board of Directors
SOUTH SAN FRANCISCO, Calif., July 31, 2026 (GLOBE NEWSWIRE) -- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to…
4 months ago seekingalpha.com
Vistagen Therapeutics, Inc. (VTGN) Discusses PALISADE-4 Phase III Results and Post-Hoc Analyses in Social Anxiety Disorder Transcript
Vistagen Therapeutics, Inc. (VTGN) Discusses PALISADE-4 Phase III Results and Post-Hoc Analyses in Social Anxiety Disorder Transcript
4 months ago benzinga.com
Penny Stock Vistagen Keeps Regulatory Plans Alive Despite Anxiety Study Miss
Vistagen Inc. (NASDAQ:VTGN) on Monday reported that its Phase 3 PALISADE-4 trial of intranasal fasedienol for the acute treatment of social anxiety disorder did not meet its primary endpoint in the…
4 months ago benzinga.com
Penny Stock Vistagen Keeps Regulatory Plans Alive Despite Anxiety Study Miss
Vistagen's Phase 3 fasedienol trial missed its main endpoint, but the company found a severe-patient signal and plans an FDA meeting.
-
4 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Creative Medical Tech (NASDAQ:CELZ) stock moved upwards by 242.5% to $2.77 during Tuesday's regular session. The market value of their outstanding shares is at $2.9 million. Cuprina Holdings…
4 months ago benzinga.com
Nasdaq Gains Over 300 Points; Chicago PMI Falls In June
US stocks traded higher, Nasdaq up 150 points. Dow up 0.02%, Nasdaq up 0.68%, S&P 500 up 0.28%. Tech shares surged, real estate stocks fell. Chicago Business Barometer declined to 56.7.
4 months ago benzinga.com
US Stocks Mixed; Home Prices Increase 1.1% In April
US stocks mixed, Dow falls 0.2%. Leading sectors: tech up 1%, real estate down 1.4%. S&P 500 up 0.09%. Edible Garden AG up 87%, Unicycive Therapeutics down 46%.
-
4 months ago benzinga.com
Vistagen Announces Topline Results From Its PALISADE-4 Phase 3 Trial Of Intranasal Fasedienol To Treat Social Anxiety Disorder; Fasedienol Did Not Achieve Its Primary Endpoint
PALISADE-4 was a U.S. multi-center, randomized, double-blind, placebo-controlled Phase 3 clinical trial designed to evaluate the efficacy, safety, and tolerability of a single dose of fasedienol in…
4 months ago businesswire.com
Vistagen Announces Topline and Post-Hoc Data from PALISADE-4 Phase 3 Public Speaking Challenge Trial of Fasedienol for the Acute Treatment of Social Anxiety Disorder
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and…
-
4 months ago benzinga.com
VistaGen Therapeutics Q4 EPS $(0.37) Misses $(0.30) Estimate, Sales $465.000K Beat $320.000K Estimate
VistaGen Therapeutics (NASDAQ:VTGN) reported quarterly losses of $(0.37) per share which missed the analyst consensus estimate of $(0.30) by 23.33 percent. This is a 15.91 percent increase over…
4 months ago businesswire.com
Vistagen Reports Fiscal Year 2026 Financial Results and Provides Corporate Update
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and…
4 months ago businesswire.com
Vistagen Achieves Minimum ICH Safety Exposure Recommendations Across Clinical Program for Fasedienol for the Acute Treatment of Social Anxiety Disorder
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and…
5 months ago gurufocus.com
Kuehn Law Encourages Investors of Vistagen Therapeutics, Inc. to Contact Law Firm
Kuehn Law Encourages Investors of Vistagen Therapeutics, Inc. to Contact Law Firm PR Newswire NEW YORK, June 1,
5 months ago prnewswire.com
Kuehn Law Encourages Investors of Vistagen Therapeutics, Inc. to Contact Law Firm
NEW YORK, June 1, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Vistagen Therapeutics, Inc. (NASDAQ: VTGN)…
5 months ago businesswire.com
Vistagen to Participate in Jefferies 2026 Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen to Participate in Jefferies 2026 Global Healthcare Conference.
5 months ago businesswire.com
Vistagen Appoints Angel S. Angelov, MD, MBA, as Chief Medical Officer
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and…
5 months ago businesswire.com
Vistagen to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen, a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new…
-
5 months ago benzinga.com
Vistagen Announces Its Data From PALISADE-3 Phase 3 Trial Of Fasedienol Demonstrates Well-Toleration, No Drug-Related Safety Concerns
Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product…
-
5 months ago benzinga.com
Vistagen Completes Last Patient Visit in PALISADE-4 Phase 3 Public Speaking Challenge Study of Fasedienol for Acute Treatment of Social Anxiety Disorder, With Topline Results Expected In Q2
Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product…
-
6 months ago benzinga.com
Vistagen Receives "Study May Proceed" Letter From FDA Under IND Application For Refisolone Nasal Spray For Treatment Of Vasomotor Symptoms Due To Menopause
Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product…
-
6 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
12 Health Care Stocks Moving In Tuesday's After-Market Session
8 months ago benzinga.com
Helus Pharma Stock Tumbles As Anxiety Drug Study Disappoints
Helus Pharma (Cybin) shares fall after Phase 2 anxiety drug results show symptom improvement, but pressure on the stock.
8 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
12 Health Care Stocks Moving In Friday's Pre-Market Session
8 months ago benzinga.com
Why Applied Materials Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
Why Applied Materials Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
8 months ago benzinga.com
Vistagen Therapeutics Earnings Report: Q3 Overview
Vistagen Therapeutics Earnings Report: Q3 Overview
-
8 months ago benzinga.com
VistaGen Therapeutics Q3 EPS $(0.45) Misses $(0.44) Estimate, Sales $303.000K Miss $366.000K Estimate
VistaGen Therapeutics (NASDAQ:VTGN) reported quarterly losses of $(0.45) per share which missed the analyst consensus estimate of $(0.44) by 2.74 percent. This is a 2.17 percent increase over losses…
8 months ago benzinga.com
Earnings Scheduled For February 12, 2026
Earnings Scheduled For February 12, 2026
-
10 months ago benzinga.com
Jefferies Downgrades Vistagen Therapeutics to Hold, Lowers Price Target to $0.9
Jefferies analyst Andrew Tsai downgrades Vistagen Therapeutics (NASDAQ:VTGN) from Buy to Hold and lowers the price target from $15 to $0.9.
10 months ago benzinga.com
Vistagen's Social Anxiety Disorder Drug Disappoints In Pivotal Late-Stage Study
Vistagen shares plunge after its Phase 3 fasedienol trial for social anxiety failed to meet the primary endpoint, despite favorable safety data.
10 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
12 Health Care Stocks Moving In Wednesday's Intraday Session
10 months ago benzinga.com
Crude Oil Rises Over 1%; General Mills Earnings Top Views
Crude Oil Rises Over 1%; General Mills Earnings Top Views
10 months ago benzinga.com
Dow Jumps 150 Points; Jabil Posts Upbeat Earnings
Dow Jumps 150 Points; Jabil Posts Upbeat Earnings